Healwell talks real-world data generation with Darwen

Executive Summary

• Healwell AI Inc. demonstrated its Darwen AI platform's capability to generate regulatory-grade real-world data (RWD) and real-world evidence (RWE) in collaboration with Takeda Pharmaceutical.
• The presentation at UEG Week in Berlin showcased AI-generated data supporting vedolizumab dose escalation for ulcerative colitis and Crohn's disease, demonstrating improved remission outcomes.
• Healwell’s Darwen AI platform is recognized as a leader in healthcare AI, validated by over 40 peer-reviewed manuscripts and named a finalist in Newsweek's inaugural AI Impact Awards 2025.

Key Details

• Collaboration Partner: Takeda Pharmaceutical (a top 20 global pharmaceutical company).
• Event: United European Gastroenterology (UEG) Week in Berlin.
• Date of Presentation: October 6, 2025.
• Therapeutic Area: Ulcerative colitis and Crohn's disease (Inflammatory bowel disease).
• Clinical Finding: AI-generated real-world data demonstrated that escalating the dose of vedolizumab from every eight weeks to every four weeks improved remission outcomes.
• Strategic Impact: The data supports label advancement and access growth for the pharmaceutical partner, aiming to improve patient outcomes in a disease area affecting approximately 2.39 million people in the US and nearly 400,000 in Canada.
• Platform Validation: Darwen AI has over 40 peer-reviewed published manuscripts validating its capabilities in clinical data abstraction and RWD/RWE generation.
• Industry Recognition: Healwell was named a finalist in Newsweek's inaugural AI Impact Awards 2025 for advancing validated, ethical AI with measurable clinical and commercial impact.

Notable Quotes

• "Our collaboration with Takeda demonstrates how our Darwen AI platform can unlock clinically meaningful insights from the wealth of data buried and not effectively used within electronic health records and documents," said Dr. Christopher Pettengell, chief medical officer.
• "By identifying patient factors that influence response, we are helping clinicians and life science partners advance more precise, effective and patient-centred care. We can see a world in which the majority of RWE will be generated by novel AI systems such as Darwen AI. This will advance the speed and accuracy with which the global pharmaceutical community can advance to improve patient outcomes."